Abstract
Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. This minireview analyzes their potential therapeutic significance in prostate cancer based on their role as androgen receptor (AR) signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A (PP2A) modulating these pathways.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Autoantigens / metabolism*
-
Cell Cycle Proteins / antagonists & inhibitors
-
Cell Cycle Proteins / metabolism*
-
Drug Resistance, Neoplasm / drug effects
-
Drug Therapy, Combination
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Intracellular Signaling Peptides and Proteins
-
Male
-
Membrane Proteins / antagonists & inhibitors
-
Membrane Proteins / metabolism*
-
Polo-Like Kinase 1
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / metabolism*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / metabolism*
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
Proto-Oncogene Proteins / metabolism*
-
Up-Regulation / drug effects
-
Wnt Signaling Pathway* / drug effects
Substances
-
Antineoplastic Agents
-
Autoantigens
-
CIP2A protein, human
-
Cell Cycle Proteins
-
Intracellular Signaling Peptides and Proteins
-
Membrane Proteins
-
Proto-Oncogene Proteins
-
Protein Serine-Threonine Kinases